

# Humphrey Fonge

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2102168/publications.pdf>

Version: 2024-02-01

45  
papers

1,379  
citations

304743

22  
h-index

345221

36  
g-index

46  
all docs

46  
docs citations

46  
times ranked

2088  
citing authors

#	ARTICLE	IF	CITATIONS
1	89Zr-Labeled Domain II-Specific scFv-Fc ImmunoPET Probe for Imaging Epidermal Growth Factor Receptor In Vivo. <i>Cancers</i> , 2021, 13, 560.	3.7	5
2	Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety. <i>BMC Cancer</i> , 2021, 21, 270.	2.6	9
3	Concussion/Mild Traumatic Brain Injury (TBI) Induces Brain Insulin Resistance: A Positron Emission Tomography (PET) Scanning Study. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9005.	4.1	8
4	Effectiveness and normal tissue toxicity of Auger electron (AE) radioimmunotherapy (RIT) with [ <sup>111</sup> In]In-Bn-DTPA-nimotuzumab in mice with triple-negative or trastuzumab-resistant human breast cancer xenografts that overexpress EGFR. <i>Nuclear Medicine and Biology</i> , 2020, 80-81, 37-44.	0.6	7
5	Nimotuzumab Site-Specifically Labeled with <sup>89</sup> Zr and <sup>225</sup> Ac Using SpyTag/SpyCatcher for PET Imaging and Alpha Particle Radioimmunotherapy of Epidermal Growth Factor Receptor Positive Cancers. <i>Cancers</i> , 2020, 12, 3449.	3.7	8
6	Development and preclinical evaluation of cixutumumab drug conjugates in a model of insulin growth factor receptor I (IGF-1R) positive cancer. <i>Scientific Reports</i> , 2020, 10, 18549.	3.3	7
7	HERG channel and cancer: A mechanistic review of carcinogenic processes and therapeutic potential. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1873, 188355.	7.4	38
8	Production and Semi-Automated Processing of <sup>89</sup> Zr Using a Commercially Available TRASIS MiniAiO Module. <i>Molecules</i> , 2020, 25, 2626.	3.8	9
9	Site-Specific Fluorescent Labeling of Antibodies and Diabodies Using SpyTag/SpyCatcher System for In Vivo Optical Imaging. <i>Molecular Imaging and Biology</i> , 2019, 21, 54-66.	2.6	28
10	<sup>111</sup> In- and <sup>225</sup> Ac-Labeled Cixutumumab for Imaging and $\alpha$ -Particle Radiotherapy of IGF-1R Positive Triple-Negative Breast Cancer. <i>Molecular Pharmaceutics</i> , 2019, 16, 4807-4816.	4.6	23
11	Preclinical Evaluation of <sup>111</sup> In-Labeled PEGylated Maytansine Nimotuzumab Drug Conjugates in EGFR-Positive Cancer Models. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1103-1110.	5.0	22
12	Therapeutic potential of nimotuzumab PEGylated-maytansine antibody drug conjugates against EGFR positive xenograft. <i>Oncotarget</i> , 2019, 10, 1031-1044.	1.8	14
13	Near infrared imaging of epidermal growth factor receptor positive xenografts in mice with domain I/II specific antibody fragments. <i>Theranostics</i> , 2019, 9, 974-985.	10.0	9
14	Next-generation sequencing-guided identification and reconstruction of antibody CDR combinations from phage selection outputs. <i>Nucleic Acids Research</i> , 2019, 47, e50-e50.	14.5	35
15	<sup>111</sup> In-Labeled Glycoprotein Nonmetastatic b (GPNMB) Targeted Gemini Surfactant-Based Nanoparticles against Melanoma: In Vitro Characterization and in Vivo Evaluation in Melanoma Mouse Xenograft Model. <i>Molecular Pharmaceutics</i> , 2019, 16, 542-551.	4.6	7
16	<sup>89</sup> Zr-nimotuzumab for immunoPET imaging of epidermal growth factor receptor I. <i>Oncotarget</i> , 2018, 9, 17117-17132.	1.8	31
17	<sup>89</sup> Zr-labeled lipoplex nanosystem for image-guided gene delivery: design, evaluation of stability and in vivo behavior. <i>International Journal of Nanomedicine</i> , 2018, Volume 13, 7801-7818.	6.7	6
18	Evaluation of antibody fragment properties for near-infrared fluorescence imaging of HER3-positive cancer xenografts. <i>Theranostics</i> , 2018, 8, 4856-4869.	10.0	24

#	ARTICLE	IF	CITATIONS
19	A novel synthetic trivalent single chain variable fragment (tri-scFv) construction platform based on the SpyTag/SpyCatcher protein ligase system. <i>BMC Biotechnology</i> , 2018, 18, 55.	3.3	17
20	<sup>99m</sup> Tc(CO) <sub>3</sub> <sup>+</sup> labeled domain I/III-specific anti-EGFR (scFv) <sub>2</sub> antibody fragment for imaging EGFR expression. <i>European Journal of Medicinal Chemistry</i> , 2018, 157, 437-446.	5.5	11
21	Near infrared fluorescence imaging of EGFR expression <i>in vivo</i> using IRDye800CW-nimotuzumab. <i>Oncotarget</i> , 2018, 9, 6213-6227.	1.8	21
22	Synthetic Modular Antibody Construction by Using the SpyTag/SpyCatcher Protein-Ligase System. <i>ChemBioChem</i> , 2017, 18, 2217-2221.	2.6	25
23	A Single-Framework Synthetic Antibody Library Containing a Combination of Canonical and Variable Complementarity-Determining Regions. <i>ChemBioChem</i> , 2017, 18, 2247-2259.	2.6	15
24	A comparison of non-biologically active truncated EGF (EGFt) and full-length hEGF for delivery of Auger electron-emitting <sup>111</sup> In to EGFR-positive breast cancer cells and tumor xenografts in athymic mice. <i>Nuclear Medicine and Biology</i> , 2015, 42, 931-938.	0.6	14
25	Positron Emission Tomographic Imaging of Iodine 124 Anti-Prostate Stem Cell Antigen Engineered Antibody Fragments in LAPC-9 Tumor Bearing Severe Combined Immunodeficiency Mice. <i>Molecular Imaging</i> , 2013, 12, 7290.2012.00033.	1.4	2
26	Estrone-3-Sulphate, a Potential Novel Ligand for Targeting Breast Cancers. <i>PLoS ONE</i> , 2013, 8, e64069.	2.5	15
27	<sup>111</sup> In-Bn-DTPA-nimotuzumab with/without modification with nuclear translocation sequence (NLS) peptides: an Auger electron-emitting radioimmunotherapeutic agent for EGFR-positive and trastuzumab (Herceptin)-resistant breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 135, 189-200.	2.5	47
28	Role of Antibody-Mediated Tumor Targeting and Route of Administration in Nanoparticle Tumor Accumulation in Vivo. <i>Molecular Pharmaceutics</i> , 2012, 9, 2168-2179.	4.6	90
29	Radiolabeled iodohypericin as tumor necrosis avid tracer: diagnostic and therapeutic potential. <i>International Journal of Cancer</i> , 2012, 131, E129-37.	5.1	42
30	Influence of formulation variables on the biodistribution of multifunctional block copolymer micelles. <i>Journal of Controlled Release</i> , 2012, 157, 366-374.	9.9	36
31	Site-specific labeling of second generation™ annexin V with <sup>99m</sup> Tc(CO) <sub>3</sub> for improved imaging of apoptosis in vivo. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 1356-1363.	3.0	35
32	In Vivo Distribution of Polymeric Nanoparticles at the Whole-Body, Tumor, and Cellular Levels. <i>Pharmaceutical Research</i> , 2010, 27, 2343-2355.	3.5	123
33	<sup>99m</sup> Tc-tricarbonyl labeled agents for cell labeling: Development, biodistribution in normal mice and preliminary in vitro evaluation. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 396-402.	3.0	7
34	Multifunctional Block Copolymer Micelles for the Delivery of <sup>111</sup> In to EGFR-Positive Breast Cancer Cells for Targeted Auger Electron Radiotherapy. <i>Molecular Pharmaceutics</i> , 2010, 7, 177-186.	4.6	30
35	The Effects of Particle Size and Molecular Targeting on the Intratumoral and Subcellular Distribution of Polymeric Nanoparticles. <i>Molecular Pharmaceutics</i> , 2010, 7, 1195-1208.	4.6	302
36	Synthesis and preliminary biological evaluation of a <sup>99m</sup> Tc-labeled hypericin derivative as a necrosis avid imaging agent. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2008, 51, 33-40.	1.0	6

#	ARTICLE	IF	CITATIONS
37	Efficient purification and metabolite analysis of radiotracers using high-performance liquid chromatography and on-line solid-phase extraction. <i>Journal of Chromatography A</i> , 2008, 1189, 323-331.	3.7	22
38	Preliminary in vivo evaluation of a novel <sup>99m</sup> Tc-Labeled HYNIC-cys-annexin A5 as an apoptosis imaging agent. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 3794-3798.	2.2	38
39	Non-invasive detection and quantification of acute myocardial infarction in rabbits using mono-[ <sup>123</sup> I]iodohypericin ASPECT. <i>European Heart Journal</i> , 2007, 29, 260-269.	2.2	68
40	Necrosis Avidity of <sup>99m</sup> Tc(CO) <sub>3</sub> -Labeled Pamoic acid Derivatives: Synthesis and Preliminary Biological Evaluation in Animal Models of Necrosis. <i>Bioconjugate Chemistry</i> , 2007, 18, 1924-1934.	3.6	24
41	Evaluation of tumor affinity of mono-[ <sup>123</sup> I]iodohypericin and mono-[ <sup>123</sup> I]iodoprotiohypericin in a mouse model with a RIF-1 tumor. <i>Contrast Media and Molecular Imaging</i> , 2007, 2, 113-119.	0.8	23
42	Synthesis and preliminary evaluation of mono-[ <sup>123</sup> I]iodohypericin monocarboxylic acid as a necrosis avid imaging agent. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 4001-4005.	2.2	24
43	Synthesis and biological evaluation of an <sup>123</sup> I-labeled bicyclic nucleoside analogue (BCNA) as potential SPECT tracer for VZV-tk reporter gene imaging. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 3458-3462.	2.2	6
44	Comparison of tridentate ligands in competition experiments for their ability to form a [ <sup>99m</sup> Tc(CO) <sub>3</sub> ] complex. <i>Tetrahedron Letters</i> , 2004, 45, 2531-2534.	1.4	35
45	Bioanalysis of tobramycin for therapeutic drug monitoring by solid-phase extraction and capillary zone electrophoresis. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004, 810, 313-318.	2.3	10